Targovax ASA’s shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange.
Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Øystein Soug, Chief Executive Officer of Targovax, said in their press release this week:
“This move marks another exciting step for Targovax. Being part of the main market is an important development for the future of the company, giving us access to a larger investor base and helping enhance our visibility. We are pleased to have had the support from the Axess market and are delighted to have been accepted on to the Oslo main market.”
The company has achieved several milestones since it listed its shares on Oslo Axess in July last year:
- Encouraging top line two-year survival data from the TG01 clinical trial in resected pancreatic cancer patients. Data showed a survival rate of 68 % from the first patient cohort compared to published historical rate of 30-53 %. This suggests a signal of clinical efficacy for the drug candidate.
- Granting of European patent for ONCOS-102, protecting Targovax’s ONCOS platform lead product until 2029.
- Strengthening the team with the appointment of Øystein Soug as Chief Executive Officer and the appointment of Erik Digman Wiklund as Chief Financial Officer.
- Presenting at a number of scientific and investor conferences.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624